



Please complete ALL information below and fax your request to 1-888-671-5285

Belbuca® Prior Authorization Request Form (Page 1 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Member Information (required) and Provider Information (required) section containing fields for Member Name, Insurance ID#, Date of Birth, Street Address, City, State, Zip, Phone, Provider Name, NPI#, Specialty, Office Phone, Office Fax, Office Street Address, City, State, Zip.

Medication Information (required) section containing fields for Medication Name, Strength, Dosage Form, and checkboxes for brand request and continuation of therapy, plus a field for Directions for Use.

Clinical Information (required) section containing instructions for terminal illness, questions about medication use, diagnosis selection (cancer-related pain, non-cancer pain, other), and questions for non-cancer pain diagnosis.



Belbuca® Prior Authorization Request Form (Page 2 of 2)
DO NOT COPY FOR FUTURE USE. FORMS ARE UPDATED FREQUENTLY AND MAY BE BARCODED

Reauthorization [Non-cancer pain only]:

If this is a reauthorization request, please answer all of the following questions:

1. What are the treatment goals for this patient? (Document treatment goals and estimated duration of treatment) _____
2. Does the treatment plan include the use of a non-opioid analgesic and/or non-pharmacologic intervention? Yes No
3. Has the patient demonstrated meaningful improvement in pain and function using a validated instrument (e.g., Brief Pain Inventory)? Yes No
4. Has the patient been screened for substance abuse/opioid dependence using a validated instrument (e.g., DAST-10)? Yes No
5. What is the rationale for not tapering and discontinuing the requested medication? (Document rationale) _____
6. Has the patient been screened for comorbid mental health conditions? Yes No
7. Is there a state prescription drug monitoring program (PDMP) available? Yes No
If **yes**, has the prescriber identified that there are NO concurrently prescribed controlled substances from the PDMP? Yes No
8. Does the prescriber acknowledge that he/she has completed an assessment of increased risk for respiratory depression in patients who have medical comorbidities or are using concurrent benzodiazepine/other drugs that could potentially cause drug-drug interactions? Yes No
9. What is the patient's total daily morphine equivalent dose? _____

Quantity limit requests:

What is the quantity requested per DAY? _____

What is the reason for exceeding the plan limitations?

- Titration or loading dose purposes
- Patient is on a dose-alternating schedule (e.g., one tablet in the morning and two tablets at night, one to two tablets at bedtime)
- Requested strength/dose is not commercially available
- Other: _____

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

Please note: This request may be denied unless all required information is received.